NASDAQ:SPPI - Spectrum Pharmaceuticals Stock Price, News & Analysis

$7.76
-0.36 (-4.43 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$7.71
Now: $7.76
$8.17
50-Day Range
$7.06
MA: $7.85
$8.62
52-Week Range
$6.22
Now: $7.76
$25.29
Volume504,557 shs
Average Volume715,818 shs
Market Capitalization$875.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.57
Spectrum Pharmaceuticals, Inc develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin's lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$109.33 million
Book Value$2.26 per share

Profitability

Net Income$-120,010,000.00
Net Margins-109.76%

Miscellaneous

Employees235
Market Cap$875.79 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.


Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.13. The biotechnology company had revenue of ($1.25) million for the quarter, compared to the consensus estimate of $0.50 million. Spectrum Pharmaceuticals had a negative net margin of 109.76% and a negative return on equity of 41.95%. The business's revenue was down 105.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.21) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Spectrum Pharmaceuticals.

What price target have analysts set for SPPI?

5 brokers have issued twelve-month price targets for Spectrum Pharmaceuticals' shares. Their predictions range from $18.00 to $40.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $23.40 in the next twelve months. This suggests a possible upside of 201.5% from the stock's current price. View Analyst Price Targets for Spectrum Pharmaceuticals.

What is the consensus analysts' recommendation for Spectrum Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spectrum Pharmaceuticals.

What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "With the sale of marketed products, Spectrum Pharma lost a steady stream of revenues. Although the BLA for Rolonits was submitted last year, it was withdrawn in March 2019. Spectrum has faced regulatory setbacks in the past including rejection of regulatory application for Qapzola seeking approval for bladder cancer in the United States. Additional regulatory/development setbacks, especially related to Rolontis, could affect the stock. Spectrum’s shares have underperformed the industry in the past year. However, development of poziotinib is progressing well including in the phase II pivotal study in second-line lung cancer. Moreover, sale of its marketed products will help Spectrum to focus on and support the development of its pipeline candidates. Loss estimates remained stable ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/1/2019)
  • 2. HC Wainwright analysts commented, "Our $40 price target is derived from an NPV of Spectrum’s proprietary pipeline, a sum-of-the-parts analysis based on the P/E value of its current commercial business, plus cash. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 3x. We value the pipeline at $12.19 per share (x3= $36.57), the current commercial business at $1.48 per share and YE18 estimated fully diluted net cash at $1.49 per share." (1/10/2019)

Has Spectrum Pharmaceuticals been receiving favorable news coverage?

News coverage about SPPI stock has been trending positive on Saturday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next few days. View News Stories for Spectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 61)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 51)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 43)
  • Mr. Keith M. McGahan J.D., L.L.M., Sr. VP, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.54%), Vanguard Group Inc. (10.69%), Primecap Management Co. CA (9.86%), Renaissance Technologies LLC (2.44%), Northern Trust Corp (1.15%) and Bank of New York Mellon Corp (1.08%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Invesco Ltd., SG Americas Securities LLC, M&T Bank Corp, BNP Paribas Arbitrage SA, Ladenburg Thalmann Financial Services Inc., Voloridge Investment Management LLC and Sargent Investment Group LLC. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Anthony E Maida III, Dolatrai Vyas, Gilles Gagnon, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, BlackRock Inc., Morgan Stanley, Vanguard Group Inc., Marshall Wace LLP, Connor Clark & Lunn Investment Management Ltd. and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $7.76.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $875.79 million and generates $109.33 million in revenue each year. The biotechnology company earns $-120,010,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Spectrum Pharmaceuticals employs 235 workers across the globe.View Additional Information About Spectrum Pharmaceuticals.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is http://www.sppirx.com/.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (NASDAQ SPPI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  391 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel